Communiqués Annexin Pharmaceuticals AB

Actions

ANNX

SE0009664154

Temps Différé Nasdaq Stockholm Autres places de cotation 13:01:36 03/07/2024			Varia. 5j.	Varia. 1 janv.
0,582 ^SEK	-3,00%		+9,40%	+123,85%

23/05	Annexin Pharmaceuticals AB (Publ) élit Mikael Lonn comme nouveau membre ordinaire du conseil d'administration	CI
30/04	Annexin Pharmaceuticals AB (Publ) annonce que l'étude de phase II a été entièrement recrutée avec des signaux positifs	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

BioStock: Annexin comments on acquisition and focus on ANXV in ophthalmology	28/06	AQ
Annexin’s rights issue 100 percent subscribed and resolution of directed issue to guarantors	30/05	AQ
Annexin celebrates 10 years and the largest owner takes a seat on the board	23/05	AQ
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	14/05	AQ
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	07/05	AQ
BioStock: Annexin's phase II study fully recruited with positive signals	30/04	AQ
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04	AQ
BioStock: Annexin towards completion of phase II study and share issue	18/04	AQ
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03	AQ
BioStock: Strong start for Annexin in 2024	14/02	AQ
Update on Annexin´s RVO study confirms promising signals of effect	08/02	AQ
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01	AQ
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18/12	AQ
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11	AQ
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28/11	AQ
First patients treated with higher dose without adverse events in Annexin's RVO study	23/11	AQ
Annexin granted additional patent protection in the US	14/11	AQ
First patient treated in the second dose group in Annexin's RVO study	25/10/23	PR
First patient treated in the second dose group in Annexin's RVO study	25/10/23	AQ
Annexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting	24/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Annexin Pharmaceuticals AB

Actions

ANNX

SE0009664154

Communiqués

Filtres